CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome

Neonatal abstinence syndrome (NAS) is a drug withdrawal syndrome that most commonly occurs in infants after in utero exposure to opioids, although other substances have also been associated with the syndrome (1). NAS usually appears within 48-72 hours of birth with a constellation of clinical signs,...

Full description

Saved in:
Bibliographic Details
Published in:MMWR. Morbidity and mortality weekly report 2017-03, Vol.66 (9), p.242-245
Main Authors: Ko, Jean Y., Wolicki, Sara, Barfield, Wanda D., Patrick, Stephen W., Broussard, Cheryl S., Yonkers, Kimberly A., Naimon, Rebecca, Iskander, John
Format: Article
Language:English
Subjects:
Care and treatment
Centers for Disease Control and Prevention, U.S
Cost of Illness
Evidence-based medicine
Female
Grand Rounds
Health Knowledge, Attitudes, Practice
Humans
Infant, Newborn
Infants (Newborn)
Legislation as Topic
Neonatal Abstinence Syndrome - epidemiology
Neonatal Abstinence Syndrome - prevention & control
Opioid-Related Disorders - epidemiology
Opioid-Related Disorders - prevention & control
Opioids
Pain
Pregnancy
Prenatal Exposure Delayed Effects
Public health
Public Health Practice
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neonatal abstinence syndrome (NAS) is a drug withdrawal syndrome that most commonly occurs in infants after in utero exposure to opioids, although other substances have also been associated with the syndrome (1). NAS usually appears within 48-72 hours of birth with a constellation of clinical signs, including central nervous system irritability (e.g., tremors), gastrointestinal dysfunction (e.g., feeding difficulties), and temperature instability (1) (Box 1). Opioid exposure during pregnancy might result from clinician-approved use of prescription opioids for pain relief; misuse or abuse of prescription opioids; illicit use (e.g., heroin); or medication-assisted treatment (MAT) of opioid use disorder (2) (Box 2).
ISSN:0149-2195
1545-861X
DOI:10.15585/mmwr.mm6609a2